Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Clinical Study of PRP (Chymotrypsinogen/Trypsinogen) in Advanced Cancer Patients Suffering from Solid Tumors Who No Longer Respond to Approved Treatment Options

Next Previous
X
Search
Trial Profile

A First-in-Human Clinical Study of PRP (Chymotrypsinogen/Trypsinogen) in Advanced Cancer Patients Suffering from Solid Tumors Who No Longer Respond to Approved Treatment Options

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chymotrypsinogen/trypsinogen (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Propanc Biopharma

    • Most Recent Events

    • 18 Dec 2023 According to a Propanc Biopharma media release, the company announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Companys lead product candidate, PRP, to the completion of the Companys planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors
    • 15 Aug 2023 According to a Propanc Biopharma media release, the companys plan is to undertake the FIH study in Australia, given the favorable R&D cashback benefit where it will receive 43% of R&D expenditure on local activities, as well as approval from the Australian Government for reimbursement some overseas activities as well. the company will undertake a Pre-IND meeting with the US Food and Drug Administration.
    • 15 Aug 2023 According to a Propanc Biopharma media release, Professor Mark Rosenthal is the Director and FIH Clinical Study Investigator at the Peter Mac Cancer Center

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top